Urokinase-type plasminogen activator (uPA) decreases hepatic SR-BI expression and impairs HDL-mediated reverse cholesterol transport

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 11-18

  Chulsky, Semyon ^a   Paland, Nicole ^a   Lazarovich, Aviva ^a   Fuhrman, Bianca ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

HDL; Reverse cholesterol transport; SR BI; Urokinase

Indexed keywords

HDL; REVERSE CHOLESTEROL TRANSPORT; SR-BI; UROKINASE;

ANIMALS; CELL LINE, TUMOR; CHOLESTEROL; CHOLESTEROL ESTERS; HEPATOCYTES; HUMANS; LIPOPROTEINS, HDL; MALE; MICE; MICE, KNOCKOUT; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SCAVENGER RECEPTORS, CLASS B; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84893873931     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.11.070     Document Type: Article

References (41)

1. Berrougui H., Momo C.N., Khalil A. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. JClin Lipidol 2012, 6:524-533.
2. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
3. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
4. Rigotti A., Miettinen H.E., Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003, 24:357-387.
5. Trigatti B.L., Krieger M., Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:1732-1738.
6. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. JBiol Chem 1998, 273:32920-32926.
7. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387:414-417.
8. Sehayek E., Ono J.G., Shefer S., et al. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci U S A 1998, 95:10194-10199.
9. Arai T., Wang N., Bezouevski M., Welch C., Tall A.R. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. JBiol Chem 1999, 274:2366-2371.
10. Krieger M., Kozarsky K. Influence of the HDL receptor SR-BI on atherosclerosis. Curr Opin Lipidol 1999, 10:491-497.
11. Braun A., Trigatti B.L., Post M.J., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002, 90:270-276.
12. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis 2012, 222:8-14.
13. Nicholl S.M., Roztocil E., Davies M.G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006, 4:101-116.
14. Cozen A.E., Moriwaki H., Kremen M., et al. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 2004, 109:2129-2135.
15. Fuhrman B., Nitzan O., Karry R., Volkova N., Dumler I., Aviram M. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis 2007, 195:e108-e116.
16. Fuhrman B., Khateeb J., Shiner M., et al. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler Thromb Vasc Biol 2008, 28:1361-1367.
17. Fuhrman B., Gantman A., Khateeb J., et al. Urokinase activates macrophage PON2 gene transcription via thePI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFR-beta. Cardiovasc Res 2009, 84:145-154.
18. Khateeb J., Kiyan Y., Aviram M., Tkachuk S., Dumler I., Fuhrman B. Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-γ nuclear export. Arterioscler Thromb Vasc Biol 2012, 32:449-458.
19. Angelin B. 1994 Mack-Forster Award Lecture. Review. Studies on the regulation of hepatic cholesterol metabolism in humans. Eur J Clin Invest 1995, 25:215-224.
20. Mito M., Kusano M., Kawaura Y. Hepatocyte transplantation in man. Transplant Proc 1992, 24:3052-3053.
21. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1983, 30:111-118.
22. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. JBiol Chem 1951, 193:265-275.
23. Aviram M., Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol 2001, 335:244-256.
24. Smythe C.D., Skinner V.O., Bruckdorfer K.R., Haskard D.O., Landis R.C. The state of macrophage differentiation determines the TNF alpha response to nitrated lipoprotein uptake. Atherosclerosis 2003, 170:213-221.
25. Maor I., Mandel H., Aviram M. Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-ketocholesterol. Arterioscler Thromb Vasc Biol 1995, 15:1378-1387.
26. Jeyakumar S.M., Vajreswari A., Giridharan N.V. Impact of vitamin A on high-density lipoprotein-cholesterol and scavenger receptor class BI in the obese rat. Obesity (Silver Spring) 2007, 15:322-329.
27. Murao K., Yu X., Imachi H., et al. Hyperglycemia suppresses hepatic scavenger receptor class B type I expression. Am J Physiol Endocrinol Metab 2008, 294:E78-E87.
28. Trigatti B. Role of the scavenger receptor class B type I in lipoprotein metabolism and atherosclerosis: insights from genetically altered mice. Biochemistry of atherosclerosis 2006, 53-69. Springer, New York. S.C. Kaur (Ed.).
29. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. JBiol Chem 1994, 269:21003-21009.
30. Truong T.Q., Brodeur M.R., Falstrault L., Rhainds D., Brissette L. Expression of caveolin-1 in hepatic cells increases oxidized LDL uptake and preserves the expression of lipoprotein receptors. JCell Biochem 2009, 108:906-915.
31. Durliat M., Komano O., Correc P., Burtin P. Areceptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity. Thromb Res 1991, 64:637-645.
32. Farris S.D., Hu J.H., Krishnan R., et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. JBiol Chem 2011, 286:22665-22677.
33. Fluiter K., van der Westhuijzen D.R., van Berkel T.J. Invivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. JBiol Chem 1998, 273:8434-8438.
34. Leiva A., Verdejo H., Benítez M.L., Martínez A., Busso D., Rigotti A. Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism. Atherosclerosis 2011, 217:299-307.
35. Shetty S., Eckhardt E.R., Post S.R., van der Westhuyzen D.R. Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes. Arterioscler Thromb Vasc Biol 2006, 26:2125-2131.
36. Silver D.L., Wang N., Tall A.R. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. JClin Invest 2000, 105:151-159.
37. de Haan W., Out R., Berbée J.F., et al. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels invivo. Biochem Biophys Res Commun 2008, 377:1294-1298.
38. Ueda Y., Gong E., Royer L., Cooper P.N., Francone O.L., Rubin E.M. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. JBiol Chem 2000, 275:20368-20373.
39. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. Atargeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997, 94:12610-12615.
40. Demetz E., Tancevski I., Duwensee K., et al. Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits. Atherosclerosis 2012, 222:360-366.
41. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output invivo in humans. JLipid Res 2004, 45:1594-1607.